Telsar

Telmisartan

Essential HTN. Reduce risk of MI, stroke or death in patients ≥55 yr at high risk of developing major CV events who are unable to take ACE inhibitors.

Adult Essential HTN 40 mg once daily, may be increased to max: 80 mg once daily. Severe HTN 160 mg alone or in combination w/ hydrochlorothiazide 12.5-25 mg daily. CV risk reduction 80 mg once daily. Mild to moderate hepatic impairment Not to exceed 40 mg once daily.

May be taken with or without food.

Hypersensitivity. Biliary obstructive disorders. Severe hepatic impairment. 2nd & 3rd trimesters of pregnancy. Lactation.

Not recommended in dual blockade of the renin-angiotensin-aldosterone system, primary aldosteronism. Not to be given in cholestasis or biliary obstructive disorders. Not to be used concomitantly w/ diabetic nephropathy. Bilateral renal artery stenosis or artery stenosis to single functioning kidney; aortic or mitral stenosis or obstructive hypertrophic cardiomyopathy; severe CHF or underlying renal disease including renal artery stenosis; hyperkalaemia; ischaemic cardiopathy or CV disease. Dehydration, acute cardiac decompensation, metabolic acidosis, infectious diseses, cellular lysis. Correct vol &/or Na depletion prior to administration. Periodic monitoring of serum K, creatinine & blood glucose levels. Concomitant use w/ K-containing salt substitutes, K-sparing diuretics, ACE inhibitors, AIIA, NSAIDs, selective COX-2 inhibitors, heparins, immunosuppressives, trimethoprim. Black patients. Not to be given in severe hepatic impairment; mild to moderate hepatic impairment. Renal impairment. Not recommended during 1st trimester of pregnancy. Not to be used during lactation. Childn & adolescents <18 yr. Elderly.

UTI, upper resp tract infections, sepsis; anaemia, eosinophilia, thrombocytopenia; anapylactic reaction, hypersensitivity; hyperkalaemia, hypoglycaemia; insomnia, depression, anxiety; syncope; visual disturbance; vertigo; bradycardia, tachycardia; hypotension, orthostatic hypotension; dyspnoea; abdominal pain, diarrhoea, dyspepsia, flatulence, vomiting, dry mouth, stomach discomfort; abnormal hepatic function; angioedema, eczema, erythema, pruritus, hyperhidrosis, urticaria, drug & toxic skin eruption, rash; back & tendon pain, muscle spasms, myalgia, arthralgia, pain in extremity; renal impairment; failure; chest pain, flu-like illness, asthenia.

Increased digoxin peak plasma & trough conc. Increased risk of hyperkalaemia w/ K-containing salt substitutes, K-sparing diuretics, K supplements, ACE inhibitors, AIIA, NSAIDs, selective COX-2 inhibitors, heparin, immunosuppressives, trimethoprim. Reversible increased serum lithium conc & toxicity. Reduced antihypertensive effect w/ NSAIDs ie, ASA, COX-2 inhibitors, non-selective NSAIDs. Increased risk of vol depletion & hypotension w/ high-dose diuretics eg, furosemide or hydrochlorothiazide. Increased BP-lowering effect w/ other antihypertensives. Potentiated hypotensive effects w/ baclofen, amifostine. Aggravated orthostatic hypotension w/ alcohol, barbiturates, narcotics or antidepressants.

Angiotensin II Antagonists

C09CA07 - telmisartan ; Belongs to the class of angiotensin II receptor blockers (ARBs). Used in the treatment of cardiovascular disease.

B